A Review of Current and Future Management of Geographic Atrophy
- PMID: 28391446
- PMCID: PMC5449305
- DOI: 10.1007/s40123-017-0086-6
A Review of Current and Future Management of Geographic Atrophy
Abstract
Age-related macular degeneration (AMD) is a multifactorial disease and a leading cause of vision impairment in elderly people in Western society. Geographic atrophy (GA), the late stage of dry AMD, is typically defined as a round or oval area of atrophy of 175 µm or more. In GA patients, visual acuity (VA) can still be good if the macula is spared, but decreased if GA extends through the fovea causing a great impairment of quality of life. Because of a poor correlation between VA and GA lesions or progression, a multimodal imaging approach is necessary to better follow up GA patients. In the last years, the introduction in clinical practice of new non-invasive tools such as fundus autofluorescence, structural optical coherence tomography (OCT) and OCT angiography helped the ophthalmologists to better understand the natural course of GA patients. However, several pathways concerning the pathogenesis of the disease are not completely clarified yet and should be investigated further. Although no approved therapy exists for GA, healthy lifestyle and nutritional intervention with some specific supplementations (e.g., vitamins C and E, beta-carotene, high dietary folate) may help to prevent the onset and to delay the progression of the disease. At the same time, several drugs are under evaluation in clinical trials with interesting results. These drugs try to stop several pathways implicated in the pathogenesis of GA, but probably only a few of these will prove truly effective, confirming the preliminary results, and will be available in clinical practice.
Keywords: Age-related macular degeneration; Antiinflammatory drugs; Dry-AMD; Geographic atrophy; Management; Neuroprotection; Nutritional supplements; Stem cell-based therapy; Vasodilators.
Figures

Similar articles
-
Recent advances in the management of dry age-related macular degeneration: A review.F1000Res. 2017 Mar 9;6:245. doi: 10.12688/f1000research.10664.1. eCollection 2017. F1000Res. 2017. PMID: 28529701 Free PMC article. Review.
-
Segmentation of the geographic atrophy in spectral-domain optical coherence tomography and fundus autofluorescence images.Invest Ophthalmol Vis Sci. 2013 Dec 30;54(13):8375-83. doi: 10.1167/iovs.13-12552. Invest Ophthalmol Vis Sci. 2013. PMID: 24265015
-
Geographic atrophy: clinical features and potential therapeutic approaches.Ophthalmology. 2014 May;121(5):1079-91. doi: 10.1016/j.ophtha.2013.11.023. Epub 2014 Jan 14. Ophthalmology. 2014. PMID: 24433969 Review.
-
Vitreoretinal interface changes in geographic atrophy.Ophthalmology. 2014 Sep;121(9):1734-9. doi: 10.1016/j.ophtha.2014.03.036. Epub 2014 May 23. Ophthalmology. 2014. PMID: 24863462
-
Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular Degeneration.Ophthalmology. 2016 May;123(5):1060-79. doi: 10.1016/j.ophtha.2016.01.034. Epub 2016 Mar 5. Ophthalmology. 2016. PMID: 26952592 Review.
Cited by
-
Yellow Subthreshold Micropulse Laser in Retinal Diseases: An In-Depth Analysis and Review of the Literature.Ophthalmol Ther. 2023 Jun;12(3):1479-1500. doi: 10.1007/s40123-023-00698-w. Epub 2023 Mar 18. Ophthalmol Ther. 2023. PMID: 36933125 Free PMC article. Review.
-
Humanistic and Economic Burden of Geographic Atrophy: A Systematic Literature Review.Clin Ophthalmol. 2021 Dec 8;15:4629-4644. doi: 10.2147/OPTH.S338253. eCollection 2021. Clin Ophthalmol. 2021. PMID: 34916775 Free PMC article. Review.
-
Imaging and artificial intelligence for progression of age-related macular degeneration.Exp Biol Med (Maywood). 2021 Oct;246(20):2159-2169. doi: 10.1177/15353702211031547. Epub 2021 Aug 18. Exp Biol Med (Maywood). 2021. PMID: 34404252 Free PMC article. Review.
-
Imaging of Geographic Atrophy: A Practical Approach.Ophthalmol Ther. 2025 Jul;14(7):1621-1632. doi: 10.1007/s40123-025-01158-3. Epub 2025 May 5. Ophthalmol Ther. 2025. PMID: 40323558 Free PMC article.
-
A Safe GDNF and GDNF/BDNF Controlled Delivery System Improves Migration in Human Retinal Pigment Epithelial Cells and Survival in Retinal Ganglion Cells: Potential Usefulness in Degenerative Retinal Pathologies.Pharmaceuticals (Basel). 2021 Jan 11;14(1):50. doi: 10.3390/ph14010050. Pharmaceuticals (Basel). 2021. PMID: 33440745 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical